Comparative Pharmacology
Head-to-head clinical analysis: AIRDUO RESPICLICK versus QVAR 80.
Head-to-head clinical analysis: AIRDUO RESPICLICK versus QVAR 80.
AIRDUO RESPICLICK vs QVAR 80
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone propionate (corticosteroid) and salmeterol (long-acting beta2-adrenergic agonist); fluticasone reduces inflammation via glucocorticoid receptor activation, salmeterol relaxes bronchial smooth muscle via beta2-receptor stimulation.
Beclomethasone dipropionate is a corticosteroid that exhibits anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, chemokines, and arachidonic acid metabolites. It also reduces edema and mucus production in the airways.
Two inhalations (55 mcg/113 mcg per inhalation) twice daily via oral inhalation; maximum 2 inhalations twice daily. For patients with asthma, starting dose is one inhalation twice daily; may increase to two inhalations twice daily after 1-2 weeks if inadequate response.
80 mcg orally via oral inhalation twice daily (maximum 320 mcg twice daily)
None Documented
None Documented
Salmeterol: terminal elimination half-life of 5.5 hours. Fluticasone furoate: terminal elimination half-life of approximately 24 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 2.9 hours after inhalation. This short half-life supports twice-daily dosing but does not fully reflect pulmonary residence time.
Renal elimination of salmeterol: approximately 25% of dose excreted unchanged in urine. Fluticasone furoate: primarily excreted as metabolites in feces (≥90%) following intravenous administration, with less than 5% excreted in urine.
Primarily hepatic metabolism, with metabolites excreted in feces (60-70%) and urine (30-40%). Less than 1% of unchanged drug is excreted in urine.
Category C
Category C
Inhaled Corticosteroid/LABA Combination
Inhaled Corticosteroid